|Articles|June 14, 2019

Almost Half of Adolescents Dont Fill Prescriptions for STIs Diagnosed in ED

Author(s)Jonna Lorenz

Failure to fill prescriptions is a common issue among adolescents diagnosed with sexually transmitted infections in emergency departments, according to a new research letter.

More than 40% of adolescents diagnosed with sexually transmitted infections (STIs) in an emergency department did not fill antibiotic prescriptions for the treatment of those infections, according to a new research letter.

The research letter, published in JAMA Pediatrics, highlighted a retrospective medical record review of visits to 2 emergency departments in Washington DC in 2016-2017 involving adolescents ages 13 to 19 years. It identified 696 ED visits during which STIs were diagnosed, resulting in 208 prescriptions for Chlamydia trachomatis (CT) cervicitis/urethritis or pelvic inflammatory disease (PID).

The study determined that 54.1% of adolescents filled their prescriptions.

“We were surprised by how few teenagers fill prescriptions they were given after STI diagnosis, and this underscores the importance of eliminating barriers that may hinder treatment adherence in this high-risk group,” the study’s senior author Monika K. Goyal, MD, MSCE, assistant chief of Children’s Division of Emergency Medicine and Trauma Services told Contagion®.

The majority of the patients included in the review were female (92.8%), and 18% were admitted to the hospital for treatment of PID. The patients in the study also were predominantly non-Hispanic black (84.1%), and publicly insured (81.6%). Prescriptions were more likely to be filled among those who were admitted to the hospital and those diagnosed with PID.

The next steps for investigators will be conducting interviews with adolescents to explore barriers to treatment adherence, Goyal said. Things to consider include costs, access to transportation and confidentiality.

“We as clinicians, health care systems and society need to do more to improve the health of adolescents,” Goyal told Contagion®. “We need to provide more education about safer sex practices and need to create access for youths to free and confidential sexual health services.”

The research letter noted that nearly half of all diagnosed STIs annually are among adolescents, and those diagnoses are often made in emergency departments.

Sexually transmitted diseases have increased sharply in recent years, with more than 2.3 million cases of chlamydia, gonorrhea, and syphilis diagnosed in the US in 2017, according to an analysis by the US Centers for Disease Control and Prevention. That represents a 31% increase from 2013.

A report published in 2017 suggested that STIs are often over- or under-treated, raising concerns about antibiotic resistance. That study found that when comparing emergency department visits from 2008-2010 with those from 2011-2013, prescriptions for azithromycin and ceftriaxone increased more than 80% in visits with an STI diagnosis and doxycycline prescriptions increased 24%.

A study released last year found that only 81% of patients infected with uncomplicated gonorrhea received the recommended treatment designed to ward off drug resistance, which includes 2 antimicrobials.


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths.¹ The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.